Difference in triptan effect in patients with migraine and early allodynia.

Author: DienerH C, HaasS, HuberG, LamplC, RittbergerE

Paper Details 
Original Abstract of the Article :
The aim of this study was to determine whether in migraine patients with and without aura early treatment with various triptans leads to differences in pain reduction after 1 h and in modulating cutaneous allodynia. Thirty-six patients with early manifestation of a clinically recognizable allodynia ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/j.1468-2982.2008.01642.x

データ提供:米国国立医学図書館(NLM)

Zooming in on Migraine and Allodynia: Exploring Triptan Efficacy

Navigating the complex world of [migraine headaches] requires a nuanced understanding of [treatment response] and [underlying mechanisms]. This study investigates the [efficacy of various triptans] in [reducing pain] and [modulating cutaneous allodynia] in [migraine patients with and without aura]. The authors employed a [randomized controlled trial] to compare the [effects of different triptans] on [pain intensity and allodynia].

A Targeted Approach: Zolmitriptan Shows Promise for Migraine With Allodynia

The research highlights that [zolmitriptan nasal spray] demonstrated [significant pain reduction] in [migraine patients with early allodynia], while other triptans did not show a significant effect. This finding suggests a [potential advantage] for [zolmitriptan] in [treating migraine patients] who experience [early allodynia].

Managing Migraine: Personalized Approaches for Effective Treatment

This study underscores the [importance of considering individual patient characteristics] when [choosing migraine treatments]. The findings suggest that [zolmitriptan] may be a [valuable option] for [patients with early allodynia], but further research is needed to [confirm its efficacy] and [explore its potential mechanisms of action].

Dr. Camel's Conclusion

This study delves deep into the intricacies of migraine and its associated symptoms, reminding us that every migraine patient is unique and requires a tailored approach to treatment. It's like exploring a hidden canyon in the desert, uncovering new insights into the complexities of this condition.

Date :
  1. Date Completed 2008-12-18
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

18624801

DOI: Digital Object Identifier

10.1111/j.1468-2982.2008.01642.x

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.